FDA seeks public input on controversial priority voucher scheme amid concerns about its transparency and legality.

Insmed’s Phase 3 trial win for Arikayce in a particular kind of lung infection sets up the drug to expand into the front-line setting —

Sanofi is back in the T cell engager business after a couple years of fluctuating interest, extending its support to a relatively unknown California startup

Pfizer’s final-stage trial of its long-awaited Lyme disease vaccine missed its primary endpoint, but the drugmaker said it still plans to try to take the

Dizal’s Zegfrovy has taken the oral EGFR inhibitor class into new territory, with a phase 3 win as a frontline treatment for a form of